Hjem › Diffust stort B-celle lymfom › Iowa
Diffust stort B-celle lymfom kliniske forsøg i Iowa
11 studier for Diffust stort B-celle lymfom søger deltagere på steder i Iowa.
Byer i Iowa
Officiel studietekst (engelsk)
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma
- Mary Greeley Medical Center, Ames
- McFarland Clinic - Ames, Ames
- UI Health Care Mission Cancer and Blood - Ankeny Clinic, Ankeny
- og 12 flere
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 1. okt. 2026 · NCT06649812Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
- Research Site, Des Moines
RekruttererFase 2
Alder 65 til 99 · Alle køn · Opdateret 29. sep. 2026 · NCT05952024A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
- University of Iowa Hospitals and Clinics, Iowa City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT05006716A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- University of Iowa-Holden Comprehensive Cancer Center ( Site 0139), Iowa City
- Mission Blood & Cancer Care ( Site 0114), Waukee
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 25. sep. 2026 · NCT06890884A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- University of Iowa, Iowa City
RekruttererFase 1
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07101328Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
- University of Iowa-Holden Comprehensive Cancer Center ( Site 1017), Iowa City
RekruttererFase 1/2
6 Months – 25 Years · Alle køn · Opdateret 17. sep. 2026 · NCT06395103Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
- Mission Blood and Cancer - MercyOne Cancer Center, Waukee
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 11. sep. 2026 · NCT06806033Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- University of Iowa, Iowa City
RekruttererFase 1/2
Alder 18 og opefter · Alle køn · Opdateret 25. aug. 2026 · NCT05826535A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- University of Iowa, Iowa City
RekruttererFase 3
Alder 18 og opefter · Alle køn · Opdateret 4. aug. 2026 · NCT07188558Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 2. feb. 2026 · NCT05633615Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
- Mercy Medical Center - Des Moines, Des Moines
RekruttererFase 2
Alder 18 og opefter · Alle køn · Opdateret 20. okt. 2025 · NCT05890352Fra ClinicalTrials.gov, data hentet 3. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.